CN102698168B - Medicine for treating cough variant asthma and preparation method of medicine - Google Patents
Medicine for treating cough variant asthma and preparation method of medicine Download PDFInfo
- Publication number
- CN102698168B CN102698168B CN2012101953250A CN201210195325A CN102698168B CN 102698168 B CN102698168 B CN 102698168B CN 2012101953250 A CN2012101953250 A CN 2012101953250A CN 201210195325 A CN201210195325 A CN 201210195325A CN 102698168 B CN102698168 B CN 102698168B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- rhizoma
- cough
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 208000006673 asthma Diseases 0.000 title claims abstract description 42
- 201000004897 cough variant asthma Diseases 0.000 title claims abstract description 29
- 229940079593 drug Drugs 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 6
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 240000007171 Imperata cylindrica Species 0.000 claims abstract 2
- 239000002994 raw material Substances 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 12
- 241000237636 Pheretima Species 0.000 claims description 12
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 11
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 7
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 7
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 7
- 235000009815 Momordica Nutrition 0.000 claims description 7
- 241000218984 Momordica Species 0.000 claims description 7
- 241001038563 Pseudostellaria Species 0.000 claims description 7
- 241000545442 Radix Species 0.000 claims description 7
- 241001180876 Saposhnikovia Species 0.000 claims description 7
- 229940097275 indigo Drugs 0.000 claims description 7
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 7
- 240000006694 Stellaria media Species 0.000 claims 1
- 206010011224 Cough Diseases 0.000 abstract description 30
- 238000012360 testing method Methods 0.000 abstract description 12
- 210000004072 lung Anatomy 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 241000596154 Belamcanda Species 0.000 abstract 1
- 244000205754 Colocasia esculenta Species 0.000 abstract 1
- 235000006481 Colocasia esculenta Nutrition 0.000 abstract 1
- 241000490229 Eucephalus Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 abstract 1
- 244000185386 Thladiantha grosvenorii Species 0.000 abstract 1
- 240000000377 Tussilago farfara Species 0.000 abstract 1
- 235000004869 Tussilago farfara Nutrition 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 241001598107 Imperata Species 0.000 description 6
- 241000722081 Stellaria <angiosperm> Species 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 239000002893 slag Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine for treating cough variant asthma. The medicine comprises 8-12 parts of momordica grosvenori, 4-8 parts of radix polygonati officinalis, 9-15 parts of radix astragali preparata, 3-7 parts of indigo naturalis, 4-8 parts of blackberry lily, 4-8 parts of rhizoma pinellinae praeparata, 4-8 parts of radix stemonae, 6-12 parts of tussilago farfara, 4-8 parts of aster, 0.8-1.2 parts of as arum, 8-12 parts of earthworm, 7-11 parts of radices stellariae dichotomae, 8-12 parts of smoked plum, 4-8 parts of radix saposhnikoviae, 8-12 parts of schisandra chinensis, 4-8 parts of radix pseudostellariae, 13-17 parts of rhizoma phragmitis and 13-17 parts of cogongrass rhizome; the medicine is beneficial to improving immunity, clearing heat, removing toxicity, clearing throats, relieving a cough, resisting allergic and preventing recurrence, has good medicine flavor, and is convenient to drink. In a word, the formula is reasonable in compatibility of medicines and is an effective prescription for taking temporary solution and effecting a permanent cure as well as treating both principal and secondary aspects of cough variant asthma. Tests show that the effective rate is up to 96.7%, no dependency or rebound phenomenon caused by drug withdrawal are generated, the medicine not only can tonify the lung and benefit qi as well as relieve a cough and asthma, but also can resist allergy and prevent recurrence, and compared with therapy by western medicines, the medicine provided by the invention has certain advantages.
Description
Technical field
The present invention relates to a kind of Chinese medicine medicine, be applicable to the treatment children chronic cough, specifically, relate to a kind of medicine and preparation method for the treatment of cough variant asthma, belong to technical field of Chinese medicines.
Background technology
Cough variant asthma is one of common cause of children chronic cough, is unique or main performance with cough, without obviously panting.Suffer from the infant of cough variant asthma in recent years and be on the increase, the peak season hospitalization phenomenon that occurs flocking together is often with acute upper respiratory tract infection companion row, good sending out in winter-spring season.
Epidemiology shows that pathogenesis of asthma is accounting for 70% below 3 years old, and cough variant asthma is in the majority at infant more than 3 years old, and repetitive upper respiratory tract infection and individual, family's allergies are arranged, and is common with allergic rhinitis.Asthma belongs to " asthma " " the syndrome of dyspnea " categories such as " coughs " in the traditional Chinese medical science.The famous old docter of TCM Wang Lie professor in the whole nation is cough variant asthma called after " heavy breathing is coughed ".The traditional Chinese medical science thinks that asthma is the card of deficiency in origin and excess in superficiality, and deficiency in origin is an endogenous cause of ill, refers to the natural endowment deficiency, and visceral dysfunction is disturbed in the retained phlegm in lung and cause, mark is real to be exopathogenic factor, refers to the exopathogen invasion, drinking and eating irregularly, overstrain, factors such as changes in temperature do not save cause retained phlegm, and mental disorder is handed over resistance, impairment of purifying and descending function of the lung, and the air flue contraction is anxious.Determine that according to infant cough degree and pathologic condition its site of pathological change and reason are most important to implementing treatment, the site of pathological change of cough variant asthma mainly occurs in trachea upper end and bottleneck throat, its pathological change is contrafluxion, ooze out, secretions increase causes the cough aggravation, moreover the participation of irritated factor, cause the prolonged and repeated outbreak of cough, have uncertainty and unstability.
In realizing process of the present invention, the inventor finds to exist at least in the prior art following problem, at present Claritin is mainly adopted in the treatment of cough variant asthma, the employing preventive usage that also has is for the not good also employing glucocorticoid treatment of the above-mentioned effect of drugs of indivedual usefulness, as oral meticorten, perhaps suck Pumi and restrain aerosol, becotide spray, general asthma can take a turn for the better, but the western medicine side effect is bigger, and the time have repeatedly, effect is undesirable.
Summary of the invention
The technical problem to be solved in the present invention is at above deficiency, and a kind of medicine for the treatment of cough variant asthma is provided, and it is bigger to have overcome the side effect of prior art Chinese medicine and western medicine, and the time have repeatedly, the unfavorable defective of effect adopts described Drug therapy cough variant asthma, and therapeutic effect is good.
Another object of the present invention provides a kind of preparation method for the treatment of the medicine of cough variant asthma.
In order to solve above technical problem, the technical solution used in the present invention is as follows: a kind of medicine for the treatment of cough variant asthma is characterized in that: the pharmacodynamic raw materials of described medicine and weight part ratio are:
Fructus Momordicae 8-12 part, Rhizoma Polygonati Odorati 4-8 part, Radix Astragali Preparata 9-15 part, Indigo Naturalis 3-7 part, Rhizoma Belamcandae 4-8 part, Rhizoma Pinelliae Preparatum 4-8 part, Radix Stemonae 4-8 part, Flos Farfarae 6-12 part, Radix Asteris 4-8 part, Herba Asari 0.8-1.2 part, Pheretima 8-12 part, Radix Stellariae 7-11 part, Fructus Mume 8-12 part, Radix Saposhnikoviae 4-8 part, Fructus Schisandrae Chinensis 8-12 part, Radix Pseudostellariae 4-8 part, Rhizoma Phragmitis 13-17 part and Rhizoma Imperatae 13-17 part.
A kind of prioritization scheme, the pharmacodynamic raw materials of described medicine and weight part ratio are: Fructus Momordicae 9-11 part, Rhizoma Polygonati Odorati 5-7 part, Radix Astragali Preparata 11-13 part, Indigo Naturalis 4-6 part, Rhizoma Belamcandae 5-7 part, Rhizoma Pinelliae Preparatum 5-7 part, Radix Stemonae 5-7 part, Flos Farfarae 7-11 part, Radix Asteris 5-7 part, Herba Asari 0.9-1.1 part, Pheretima 9-11 part, Radix Stellariae 8-10 part, Fructus Mume 9-11 part, Radix Saposhnikoviae 5-7 part, Fructus Schisandrae Chinensis 9-11 part, Radix Pseudostellariae 5-7 part, Rhizoma Phragmitis 14-16 part and Rhizoma Imperatae 14-16 part.
Another kind of prioritization scheme, the pharmacodynamic raw materials of described medicine and weight part ratio are: 15 parts of 10 parts of Fructus Momordicaes, 6 parts of Rhizoma Polygonati Odorati, 12 parts of Radix Astragali Preparatas, 5 parts of Indigo Naturaliss, 6 parts of Rhizoma Belamcandae, 6 parts of Rhizoma Pinelliae Preparatum, 6 parts of the Radixs Stemonae, 8 parts of Flos Farfaraees, 6 parts of Radix Asteriss, 1 part of Herba Asari, 10 parts of Pheretimas, 9 parts of Radix Stellariaes, 10 parts of Fructus Mumes, 6 parts of Radix Saposhnikoviaes, 10 parts of Fructus Schisandrae Chinensis, 6 parts of Radix Pseudostellariaes, 15 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Based on the medicine of above treatment cough variant asthma, the present invention provides a kind of described treatment cough again
The preparation method of the medicine of variant asthma is characterized in that: described preparation method comprises the steps:
Place pot to soak decocting after 20 minutes described raw material, change warm fire after boiling and continued to fry in shallow oil 15-30 minute, remove slag medicine juice 60-70 milliliter;
Then medicinal residues are placed once more pot to soak decocting after 20 minutes, change warm fire after boiling and continued to fry in shallow oil 15-30 minute, remove slag medicine juice 60-70 milliliter;
The medicine of cough variant asthma will must be treated after twice gained medicine juice mixing.
In the above composition,
The Radix Astragali Preparata tonifying Qi and lifting yang is used for spleen, insufficiency of lung-QI, all can spleen reinforcing, the medicine of the insufficiency of lung-QI yang invigorating immunologic function that is improved; Indigo Naturalis, Rhizoma Belamcandae heat-clearing and toxic substances removing, removing heat from blood, dispelling phlegm and relieving sore-throat are specially controlled diseases such as laryngopharynx swelling and pain and abundant expectoration asthma; Lung is supported in Fructus Momordicae, Rhizoma Polygonati Odorati, Radix Pseudostellariae yin nourishing, and cough-relieving is promoted the production of body fluid, in order to treat pharyngodynia with dryness etc.; Rhizoma Pinelliae Preparatum, the Radix Stemonae, Flos Farfarae, Radix Asteris four medicines share and can produce antiasthmatic-antitussive widely, nourishing the lung to arrest cough, preventing phlegm from forming and stopping coughing, the effect of clearing phlegm and relieving cough, be used for cough with dyspnea, various coughs such as it is not well to cough up phlegm are evident in efficacy, and Herba Asari, Pheretima are to control heavy breathing, relieving asthma, press down the strong lung of breathing heavily, reduce phlegm and effectively fill a prescription; Radix Stellariae, Fructus Mume, Radix Saposhnikoviae, Fructus Schisandrae Chinensis are traditional antiallergic good recipe, have good anti-allergic effects, all can use in asthma attack phase or catabasis; Rhizoma Phragmitis clearing stomach preventing or arresting vomiting, clearing away lung-heat to relieve cough; Rhizoma Imperatae removing heat from blood, hemostasis can reduce bottleneck throat hyperemia, edema and ooze out, and add Indigo Naturalis, the sharp larynx combined effect of Rhizoma Belamcandae heat clearing away, can repair function be arranged to the pathological change that bronchitis produces.Simultaneously sweet, flat, sour, the temperature of Rhizoma Phragmitis, Rhizoma Imperatae, Fructus Mume, Fructus Schisandrae Chinensis nature and flavor plays the flavoring agent effect, has solved children's and has drunk a difficult problem in the Chinese medicine.
The present invention takes above technical scheme, compared with prior art, has the following advantages: improve immunity, and heat-clearing and toxic substances removing, clearing throat, relieving cough and relieving asthma, the anti-recurrence of antiallergic, the medicine features good taste is convenient to drink; In a word, this side's compatibility is reasonable, be cough variation asthma take stopgap measures effect a permanent cure, effective prescription for the treatment of both the principal and secondary aspects of a disease, through test, effective percentage reaches 96.7%, and does not have obvious toxic-side effects, does not also produce dependency and rebound phenomenon occurs because of drug withdrawal, can invigorating the lung and benefiting vital QI, relieving cough and asthma can antiallergic be prevented recurrence again, and these have compared certain advantage with western medicine.
The invention will be further described below in conjunction with embodiment.
The specific embodiment
Embodiment 1, a kind of medicine for the treatment of cough variant asthma, pharmacodynamic raw materials and weight part ratio are: 13 parts of 8 parts of Fructus Momordicaes, Rhizoma Polygonati Odorati 4,15 parts of Radix Astragali Preparatas, 3 parts of Indigo Naturaliss, 8 parts of Rhizoma Belamcandae, 8 parts of Rhizoma Pinelliae Preparatum, 4 parts of the Radixs Stemonae, 12 parts of Flos Farfaraees, 4 parts of Radix Asteriss, 0.8 part of Herba Asari, 8 parts of Pheretimas, 7 parts of Radix Stellariaes, 12 parts of Fructus Mumes, 8 parts of Radix Saposhnikoviaes, 8 parts of Fructus Schisandrae Chinensis, 4 parts of Radix Pseudostellariaes, 13 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Embodiment 2, a kind of medicine for the treatment of cough variant asthma, pharmacodynamic raw materials and weight part ratio are: 17 parts of 12 parts of Fructus Momordicaes, 8 parts of Rhizoma Polygonati Odorati, 9 parts of Radix Astragali Preparatas, 7 parts of Indigo Naturaliss, 4 parts of Rhizoma Belamcandae, 4 parts of Rhizoma Pinelliae Preparatum, 8 parts of the Radixs Stemonae, 6 parts of Flos Farfaraees, 8 parts of Radix Asteriss, 1.2 parts of Herba Asaris, 12 parts of Pheretimas, 11 parts of Radix Stellariaes, 8 parts of Fructus Mumes, 4 parts of Radix Saposhnikoviaes, 12 parts of Fructus Schisandrae Chinensis, 8 parts of Radix Pseudostellariaes, 17 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Embodiment 3, a kind of medicine for the treatment of cough variant asthma, pharmacodynamic raw materials and weight part ratio are: 16 parts of 11 parts of Fructus Momordicaes, 5 parts of Rhizoma Polygonati Odorati, 13 parts of Radix Astragali Preparatas, 6 parts of Indigo Naturaliss, 7 parts of Rhizoma Belamcandae, 5 parts of Rhizoma Pinelliae Preparatum, 7 parts of the Radixs Stemonae, 7 parts of Flos Farfaraees, 5 parts of Radix Asteriss, 0.9 part of Herba Asari, 11 parts of Pheretimas, 10 parts of Radix Stellariaes, 11 parts of Fructus Mumes, 5 parts of Radix Saposhnikoviaes, 11 parts of Fructus Schisandrae Chinensis, 7 parts of Radix Pseudostellariaes, 14 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Embodiment 4, a kind of medicine for the treatment of cough variant asthma, pharmacodynamic raw materials and weight part ratio are: 14 parts of 9 parts of Fructus Momordicaes, 7 parts of Rhizoma Polygonati Odorati, 11 parts of Radix Astragali Preparatas, 4 parts of Indigo Naturaliss, 5 parts of Rhizoma Belamcandae, 5 parts of Rhizoma Pinelliae Preparatum, 5 parts of the Radixs Stemonae, 11 parts of Flos Farfaraees, 7 parts of Radix Asteriss, 1.1 parts of Herba Asaris, 9 parts of Pheretimas, 8 parts of Radix Stellariaes, 9 parts of Fructus Mumes, 7 parts of Radix Saposhnikoviaes, 9 parts of Fructus Schisandrae Chinensis, 5 parts of Radix Pseudostellariaes, 16 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Embodiment 5, a kind of medicine for the treatment of cough variant asthma, pharmacodynamic raw materials and weight part ratio are: 15 parts of 10 parts of Fructus Momordicaes, 6 parts of Rhizoma Polygonati Odorati, 12 parts of Radix Astragali Preparatas, 5 parts of Indigo Naturaliss, 6 parts of Rhizoma Belamcandae, 6 parts of Rhizoma Pinelliae Preparatum, 6 parts of the Radixs Stemonae, 8 parts of Flos Farfaraees, 6 parts of Radix Asteriss, 1 part of Herba Asari, 10 parts of Pheretimas, 9 parts of Radix Stellariaes, 10 parts of Fructus Mumes, 6 parts of Radix Saposhnikoviaes, 10 parts of Fructus Schisandrae Chinensis, 6 parts of Radix Pseudostellariaes, 15 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
More than the medicine of five embodiment prepare according to following steps respectively:
Place pot to soak decocting after 20 minutes described raw material, change warm fire after boiling and continued to fry in shallow oil 15-30 minute, remove slag medicine juice 60-70 milliliter;
Then medicinal residues are placed once more pot to soak decocting after 20 minutes, change warm fire after boiling and continued to fry in shallow oil 15-30 minute, remove slag medicine juice 60-70 milliliter;
The medicine of cough variant asthma will must be treated after twice gained medicine juice mixing.
Sooner or later respectively obey the 50-70 milliliter every day, and be 1 course of treatment January.The period in a medicine preventing cold is avoided edible over-salty, is crossed the sweet food thing, and repeatedly drinks boiled water on a small quantity.
Above five embodiment gained medicines are used for the treatment of the test of cough variant asthma, use efficacy assessment standard to be:
Recovery from illness: the cough complete obiteration, do not cough when motion or chance cold air yet; Produce effects: cough disappears, and idol has dry cough when motion or chance cold air; Effectively: cough alleviates, and cough occurs when motion or chance cold air, but number of times reduces obviously; Invalid: cough does not have obviously change.
Choose 180 examples from the outpatient service infant of seeking medical advice year October in November, 2010 to 2011, wherein male 96 examples, women 84 examples, age 3-6 year, course of disease 1-2 month; All infants all meet " the sick diagnostic criteria of pediatrics cough variant asthma: long-term dry cough is all arranged, few expectorant or do not have expectorant, night and time-out outbreak in morning are moved, are met cold air or smell the special odor postemphasis, nothing is panted.Check visible pharyngeal congestion, two upward pulmonary respiration sounds are slightly thick, do not have obvious dried moist rales, and lab testing tip blood leukocytes is counted normally or omit high, and rabat is no abnormal.
5 test group are set altogether, and each test group random assortment patient treats.Test group 1 is used the Drug therapy of embodiment 1 gained, test group 2 is used the Drug therapy of embodiment 2 gained, test group 3 is used the Drug therapy of embodiment 3 gained, and test group 4 is used the Drug therapy of embodiment 4 gained, and test group 5 is used the Drug therapy of the embodiment of the invention 5 gained, if 30 examples are matched group, matched group adopts children's's cefaclor granule, particles for eliminating phlegm and stopping cough for children, and ketotifen is oral, treating January was 1 course of treatment, total effective rate 80%.
Result such as following table that test obtains:
Find out from above data, the medicine of gained treatment cough variant asthma of the present invention, total effective rate reaches more than 90.0%, and in above embodiment, embodiment 5 is a preferred plan.
Those skilled in the art will recognize that; the above-mentioned specific embodiment is exemplary; be in order to make those skilled in the art can better understand content of the present invention; should not be construed as is limiting the scope of the invention; so long as the improvement of doing according to technical solution of the present invention; and realization and identical effect of the present invention, all fall into protection scope of the present invention.
Claims (3)
1. medicine for the treatment of cough variant asthma, it is characterized in that: the pharmacodynamic raw materials of described medicine and weight part ratio are:
Fructus Momordicae 8-12 part, Rhizoma Polygonati Odorati 4-8 part, Radix Astragali Preparata 9-15 part, Indigo Naturalis 3-7 part, Rhizoma Belamcandae 4-8 part, Rhizoma Pinelliae Preparatum 4-8 part, Radix Stemonae 4-8 part, Flos Farfarae 6-12 part, Radix Asteris 4-8 part, Herba Asari 0.8-1.2 part, Pheretima 8-12 part, Radix Stellariae 7-11 part, Fructus Mume 8-12 part, Radix Saposhnikoviae 4-8 part, Fructus Schisandrae Chinensis 8-12 part, Radix Pseudostellariae 4-8 part, Rhizoma Phragmitis 13-17 part and Rhizoma Imperatae 13-17 part.
2. a kind of according to claim 1 medicine for the treatment of cough variant asthma, it is characterized in that: the pharmacodynamic raw materials of described medicine and weight part ratio are: Fructus Momordicae 9-11 part, Rhizoma Polygonati Odorati 5-7 part, Radix Astragali Preparata 11-13 part, Indigo Naturalis 4-6 part, Rhizoma Belamcandae 5-7 part, Rhizoma Pinelliae Preparatum 5-7 part, Radix Stemonae 5-7 part, Flos Farfarae 7-11 part, Radix Asteris 5-7 part, Herba Asari 0.9-1.1 part, Pheretima 9-11 part, Radix Stellariae 8-10 part, Fructus Mume 9-11 part, Radix Saposhnikoviae 5-7 part, Fructus Schisandrae Chinensis 9-11 part, Radix Pseudostellariae 5-7 part, Rhizoma Phragmitis 14-16 part and Rhizoma Imperatae 14-16 part.
3. a kind of according to claim 1 medicine for the treatment of cough variant asthma, it is characterized in that: the pharmacodynamic raw materials of described medicine and weight part ratio are: 15 parts of 10 parts of Fructus Momordicaes, 6 parts of Rhizoma Polygonati Odorati, 12 parts of Radix Astragali Preparatas, 5 parts of Indigo Naturaliss, 6 parts of Rhizoma Belamcandae, 6 parts of Rhizoma Pinelliae Preparatum, 6 parts of the Radixs Stemonae, 8 parts of Flos Farfaraees, 6 parts of Radix Asteriss, 1 part of Herba Asari, 10 parts of Pheretimas, 9 parts of Radix Stellariaes, 10 parts of Fructus Mumes, 6 parts of Radix Saposhnikoviaes, 10 parts of Fructus Schisandrae Chinensis, 6 parts of Radix Pseudostellariaes, 15 parts of Rhizoma Phragmitiss and Rhizoma Imperataes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101953250A CN102698168B (en) | 2012-06-14 | 2012-06-14 | Medicine for treating cough variant asthma and preparation method of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012101953250A CN102698168B (en) | 2012-06-14 | 2012-06-14 | Medicine for treating cough variant asthma and preparation method of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102698168A CN102698168A (en) | 2012-10-03 |
| CN102698168B true CN102698168B (en) | 2013-07-24 |
Family
ID=46891415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012101953250A Active CN102698168B (en) | 2012-06-14 | 2012-06-14 | Medicine for treating cough variant asthma and preparation method of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102698168B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103549080B (en) * | 2013-10-29 | 2014-09-17 | 黄毅青 | Lung-clearing tea |
| CN109106894A (en) * | 2018-09-27 | 2019-01-01 | 无锡济民可信山禾药业股份有限公司 | A kind of Chinese medicine composition for treating Children with Irrtability Cough |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683422A (en) * | 2008-09-26 | 2010-03-31 | 北京以岭药业有限公司 | Applications of traditional Chinese medicine composition in preparation of medicament for treating cough variant asthma |
-
2012
- 2012-06-14 CN CN2012101953250A patent/CN102698168B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101683422A (en) * | 2008-09-26 | 2010-03-31 | 北京以岭药业有限公司 | Applications of traditional Chinese medicine composition in preparation of medicament for treating cough variant asthma |
Non-Patent Citations (4)
| Title |
|---|
| 中医辨证治疗小儿咳嗽变异性哮喘;王琦;《中医儿科杂志》;20090930;第5卷(第5期);22-23 * |
| 咳嗽变异性哮喘的中医药研究近况;罗社文等;《北京中医杂志》;20030228;第22卷(第1期);52-55 * |
| 王琦.中医辨证治疗小儿咳嗽变异性哮喘.《中医儿科杂志》.2009,第5卷(第5期),22-23. |
| 罗社文等.咳嗽变异性哮喘的中医药研究近况.《北京中医杂志》.2003,第22卷(第1期),52-55. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102698168A (en) | 2012-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102743737B (en) | Chinese medicinal preparation for effectively treating tracheitis | |
| CN102125651A (en) | Chinese medicinal throat-disinhibiting tea for treating chronic pharyngitis | |
| CN102698168B (en) | Medicine for treating cough variant asthma and preparation method of medicine | |
| CN103623220A (en) | Traditional Chinese medicine for treating lung cancer and branchiectasis hemoptysis | |
| CN103520514A (en) | Traditional Chinese medicinal decoction for treating cough-type asthma of children | |
| CN103230510A (en) | Medicament for treating bronchitis | |
| CN102949593A (en) | Medicament for moistening lung and arresting cough | |
| CN105998720A (en) | Chinese medicinal preparation for treatment of children bronchial pneumonia and preparation method | |
| CN102058766A (en) | Formula of traditional Chinese medicine for treating anemopyretic cold | |
| CN104491820A (en) | Traditional Chinese medicine formula for treating pediatric pertussis | |
| CN105617321A (en) | Decoction medicine for treating phlegm heat cough and preparation method thereof | |
| CN105878878A (en) | Cough black plaster | |
| CN100998745A (en) | Oral traditional Chinese medicine for treating asthma of deficiency of yin | |
| CN105213751A (en) | A kind of Chinese medicine composition for the treatment of cough | |
| CN105797007A (en) | Decoction medicine for treatment of pneumonia and preparation method thereof | |
| CN105250673A (en) | Medicine composition for treatment of yin deficiency and preparation method and application thereof | |
| CN105561007A (en) | Traditional Chinese medicine preparation for treating infantile influenza and preparation method | |
| CN104491790A (en) | Traditional Chinese medicine for treating chronic pharyngitis | |
| CN104840795A (en) | Traditional Chinese medicine composition for treating infantile dry cough | |
| CN104491537A (en) | Traditional Chinese medicine composition for treating rheumatic heart disease | |
| CN102380035B (en) | Common coltsfoot flower, dwarf lilyturf tuber, white mulberry root-bark, ginkgo seed, whiteflower hogfennel root, elaeagnus pungens and Chinese wolfberry root-bark decoction for treating bronchial asthma | |
| CN104491275A (en) | Traditional Chinese medicine preparation for nursing haemorrhoids and preparation method thereof | |
| CN104398902A (en) | Deficiency-cold type chronic bronchitis treating preparation for clearing away heat and dispersing lung and preparation method of preparation | |
| CN104800368A (en) | Medicinal composition for treating bronchiectasis, and formation method thereof | |
| CN104127504B (en) | Infantile common cold cough syrup and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Huixiang Inventor after: Wang Zhenyou Inventor before: Wang Zhenyou |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG ZHENYOU TO: YANG HUIXIANG WANG ZHENYOU |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG FANGDU HIGH-TECH VENTURE PARK SERVICE CO., Free format text: FORMER OWNER: WANG ZHENYOU Effective date: 20140626 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 262700 WEIFANG, SHANDONG PROVINCE TO: 226112 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140626 Address after: 226112, Jiangsu, Nantong Haimen town Sanxing village 15 groups Patentee after: Nantong Textile Science and Technology Pioneer Park Service Co.,Ltd. Address before: 262700 Shouguang County, Shouguang City, Shandong Province, Weifang Xinxing Street East Shouguang City Hospital Patentee before: Wang Zhenyou |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 226112, Jiangsu, Nantong Haimen town Sanxing village 15 groups Patentee after: Nantong textile Capital Management Co.,Ltd. Address before: 226112, Jiangsu, Nantong Haimen town Sanxing village 15 groups Patentee before: Nantong Textile Science and Technology Pioneer Park Service Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200617 Address after: Sanxing Zhen Nan Cun, Haimen City, Nantong City, Jiangsu Province Patentee after: Jiangsu Dieshiqiao Investment Co.,Ltd. Address before: 226112, Jiangsu, Nantong Haimen town Sanxing village 15 groups Patentee before: Nantong textile Capital Management Co.,Ltd. |